Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1Bronchial Neoplasms 1

Interventions

Specimen Handling 53pembrolizumab 51Carboplatin 51Magnetic Resonance Spectroscopy 46Pemetrexed 41Cisplatin 36Paclitaxel 25durvalumab 24osimertinib 22Nivolumab 22Gemcitabine 20Radiosurgery 18Radiotherapy 17Docetaxel 17atezolizumab 15Immunoglobulin G 15Biopsy 15Disulfides 14130-nm albumin-bound paclitaxel 13Taxes 12Radiation 12Educational Status 12Etoposide 11Blood Specimen Collection 11Early Intervention, Educational 10Drug Therapy 10Practice Guidelines as Topic 9Platinum 9Methods 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Toll-Like Receptor 1 × 90 days × Clear all
NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡